Wei-Han Cheng, Kinga Borsos, Zhixiao Wang, Olivier Ledanois, Rebecca Gall, Mark Small, Richard Humphreys
{"title":"儿童哮喘患者的疾病负担和未满足的临床需求:来自美国和五个欧洲国家的真实世界经验。","authors":"Wei-Han Cheng, Kinga Borsos, Zhixiao Wang, Olivier Ledanois, Rebecca Gall, Mark Small, Richard Humphreys","doi":"10.1080/02770903.2025.2513059","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Childhood asthma is a multifaceted, chronic respiratory disease; data on its burden in real-world settings are still scarce. We aimed to assess the burden of pediatric asthma and challenges with current management.</p><p><strong>Methods: </strong>Data were drawn from the Adelphi Disease Specific Programme™, a cross-sectional survey of physicians, pediatric patients with moderate and severe asthma, and their parents/guardians in five European countries and the United States between July 2021 and February 2022 (index). Demographics, clinical characteristics, diagnostic tests, symptoms, treatment patterns, and healthcare resource utilization data were collected from 12 months pre-index period or medical history, stratified by 2- to 5- and 6- to <12-year age groups.</p><p><strong>Results: </strong>Data on 1332 patients were collected (mean age, 7.8 years; physician-confirmed asthma, 80.3%). Overall, 92% of patients were perceived as having moderate asthma; ∼51% had type 2 (T2) comorbidities. Significant inter-country differences (<i>p</i> < .05) were observed for ethnicity, confirmed asthma diagnosis, receipt of asthma medication, and ongoing T2 comorbidities in the 6 to <12 years age group. Approximately, 80% of patients experienced at least one asthma-related symptom in the past 4 weeks, including shortness of breath (21.0%), wheezing (31.0%), and persistent cough (23.0%). Inhaled corticosteroids plus short-acting drugs were prescribed to one-fourth of patients aged 6 to <12 years. Of all, 62% patients had experienced at least one exacerbation in the past 12 months.</p><p><strong>Conclusions: </strong>In our study, a substantial proportion of pediatric asthma patients had T2 comorbidities, high symptomatic burden, and elevated risk of exacerbations, highlighting an unmet need in disease management.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1698-1711"},"PeriodicalIF":1.3000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Burden of disease and unmet clinical needs in pediatric patients with asthma: real-world experience from the United States and five European countries.\",\"authors\":\"Wei-Han Cheng, Kinga Borsos, Zhixiao Wang, Olivier Ledanois, Rebecca Gall, Mark Small, Richard Humphreys\",\"doi\":\"10.1080/02770903.2025.2513059\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Childhood asthma is a multifaceted, chronic respiratory disease; data on its burden in real-world settings are still scarce. We aimed to assess the burden of pediatric asthma and challenges with current management.</p><p><strong>Methods: </strong>Data were drawn from the Adelphi Disease Specific Programme™, a cross-sectional survey of physicians, pediatric patients with moderate and severe asthma, and their parents/guardians in five European countries and the United States between July 2021 and February 2022 (index). Demographics, clinical characteristics, diagnostic tests, symptoms, treatment patterns, and healthcare resource utilization data were collected from 12 months pre-index period or medical history, stratified by 2- to 5- and 6- to <12-year age groups.</p><p><strong>Results: </strong>Data on 1332 patients were collected (mean age, 7.8 years; physician-confirmed asthma, 80.3%). Overall, 92% of patients were perceived as having moderate asthma; ∼51% had type 2 (T2) comorbidities. Significant inter-country differences (<i>p</i> < .05) were observed for ethnicity, confirmed asthma diagnosis, receipt of asthma medication, and ongoing T2 comorbidities in the 6 to <12 years age group. Approximately, 80% of patients experienced at least one asthma-related symptom in the past 4 weeks, including shortness of breath (21.0%), wheezing (31.0%), and persistent cough (23.0%). Inhaled corticosteroids plus short-acting drugs were prescribed to one-fourth of patients aged 6 to <12 years. Of all, 62% patients had experienced at least one exacerbation in the past 12 months.</p><p><strong>Conclusions: </strong>In our study, a substantial proportion of pediatric asthma patients had T2 comorbidities, high symptomatic burden, and elevated risk of exacerbations, highlighting an unmet need in disease management.</p>\",\"PeriodicalId\":15076,\"journal\":{\"name\":\"Journal of Asthma\",\"volume\":\" \",\"pages\":\"1698-1711\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Asthma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02770903.2025.2513059\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02770903.2025.2513059","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:儿童哮喘是一种多面性慢性呼吸道疾病;有关其在现实环境中的负担的数据仍然很少。我们的目的是评估儿童哮喘的负担和当前管理的挑战。方法数据来自阿德尔菲病特定项目(Adelphi Disease Specific program),该项目是一项针对5个欧洲国家和美国的医生、中度和重度哮喘儿科患者及其父母/监护人的横断面调查,调查时间为2021年7月至2022年2月。人口统计学、临床特征、诊断测试、症状、治疗模式和医疗资源利用数据收集自指数前12个月或病史,按2- 5和6- p分层
Burden of disease and unmet clinical needs in pediatric patients with asthma: real-world experience from the United States and five European countries.
Objective: Childhood asthma is a multifaceted, chronic respiratory disease; data on its burden in real-world settings are still scarce. We aimed to assess the burden of pediatric asthma and challenges with current management.
Methods: Data were drawn from the Adelphi Disease Specific Programme™, a cross-sectional survey of physicians, pediatric patients with moderate and severe asthma, and their parents/guardians in five European countries and the United States between July 2021 and February 2022 (index). Demographics, clinical characteristics, diagnostic tests, symptoms, treatment patterns, and healthcare resource utilization data were collected from 12 months pre-index period or medical history, stratified by 2- to 5- and 6- to <12-year age groups.
Results: Data on 1332 patients were collected (mean age, 7.8 years; physician-confirmed asthma, 80.3%). Overall, 92% of patients were perceived as having moderate asthma; ∼51% had type 2 (T2) comorbidities. Significant inter-country differences (p < .05) were observed for ethnicity, confirmed asthma diagnosis, receipt of asthma medication, and ongoing T2 comorbidities in the 6 to <12 years age group. Approximately, 80% of patients experienced at least one asthma-related symptom in the past 4 weeks, including shortness of breath (21.0%), wheezing (31.0%), and persistent cough (23.0%). Inhaled corticosteroids plus short-acting drugs were prescribed to one-fourth of patients aged 6 to <12 years. Of all, 62% patients had experienced at least one exacerbation in the past 12 months.
Conclusions: In our study, a substantial proportion of pediatric asthma patients had T2 comorbidities, high symptomatic burden, and elevated risk of exacerbations, highlighting an unmet need in disease management.
期刊介绍:
Providing an authoritative open forum on asthma and related conditions, Journal of Asthma publishes clinical research around such topics as asthma management, critical and long-term care, preventative measures, environmental counselling, and patient education.